株探米国株
英語
エドガーで原本を確認する
Bioceres Crop Solutions Corp.0001769484--06-302024Q1false2023-09-3000017694842023-07-012023-09-300001769484ifrs-full:ParentMember2023-09-300001769484ifrs-full:ParentMember2023-06-300001769484biox:TrustDebtSecuritiesMember2023-09-300001769484biox:ParentsCompaniesAndRelatedPartiesMember2023-09-300001769484biox:TrustDebtSecuritiesMember2023-06-300001769484biox:ParentsCompaniesAndRelatedPartiesMember2023-06-300001769484biox:TrigallGeneticsS.a.Member2023-07-012023-09-300001769484biox:SynertechIndustriasS.aMember2023-07-012023-09-300001769484biox:TrigallGeneticsS.a.Member2022-07-012022-09-300001769484biox:SynertechIndustriasS.aMember2022-07-012022-09-300001769484ifrs-full:CurrencyRiskMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2023-06-300001769484biox:GoodsAndServicesIncludingRightOfUseLicenseMemberbiox:SeedAndIntegratedProductsMember2023-07-012023-09-300001769484biox:GoodsAndServicesIncludingRightOfUseLicenseMemberbiox:CropProtectionMember2023-07-012023-09-300001769484biox:GoodsAndServicesIncludingRightOfUseLicenseMemberbiox:CropNutritionMember2023-07-012023-09-300001769484biox:GoodsAndServicesMember2023-07-012023-09-300001769484biox:GoodsAndServicesIncludingRightOfUseLicenseMember2023-07-012023-09-300001769484biox:GoodsAndServicesIncludingRightOfUseLicenseMemberbiox:SeedAndIntegratedProductsMember2022-07-012022-09-300001769484biox:GoodsAndServicesIncludingRightOfUseLicenseMemberbiox:CropProtectionMember2022-07-012022-09-300001769484biox:GoodsAndServicesIncludingRightOfUseLicenseMemberbiox:CropNutritionMember2022-07-012022-09-300001769484biox:GoodsAndServicesMember2022-07-012022-09-300001769484biox:GoodsAndServicesIncludingRightOfUseLicenseMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:FixturesAndFittingsMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:VehiclesMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OfficeEquipmentMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:MachineryMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:FixturesAndFittingsMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerEquipmentMember2023-09-300001769484ifrs-full:VehiclesMember2023-09-300001769484ifrs-full:OfficeEquipmentMember2023-09-300001769484ifrs-full:MachineryMember2023-09-300001769484ifrs-full:LandAndBuildingsMember2023-09-300001769484ifrs-full:FixturesAndFittingsMember2023-09-300001769484ifrs-full:ConstructionInProgressMember2023-09-300001769484ifrs-full:ComputerEquipmentMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:FixturesAndFittingsMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:VehiclesMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OfficeEquipmentMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:MachineryMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:FixturesAndFittingsMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerEquipmentMember2023-06-300001769484ifrs-full:VehiclesMember2023-06-300001769484ifrs-full:OfficeEquipmentMember2023-06-300001769484ifrs-full:MachineryMember2023-06-300001769484ifrs-full:LandAndBuildingsMember2023-06-300001769484ifrs-full:FixturesAndFittingsMember2023-06-300001769484ifrs-full:ConstructionInProgressMember2023-06-300001769484ifrs-full:ComputerEquipmentMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:FixturesAndFittingsMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:VehiclesMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OfficeEquipmentMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:MachineryMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:FixturesAndFittingsMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerEquipmentMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:FixturesAndFittingsMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:VehiclesMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OfficeEquipmentMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:MachineryMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:FixturesAndFittingsMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerEquipmentMember2022-06-300001769484ifrs-full:RetainedEarningsMember2023-07-012023-09-300001769484ifrs-full:RetainedEarningsMember2022-07-012022-09-300001769484biox:ReceivablesForPpESalesMember2023-09-300001769484ifrs-full:OtherRelatedPartiesMember2023-06-300001769484biox:ReceivablesForPpESalesMember2023-06-300001769484ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-07-012023-09-300001769484ifrs-full:NoncontrollingInterestsMember2023-07-012023-09-300001769484ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-07-012022-09-300001769484ifrs-full:PreferenceSharesMember2023-09-300001769484ifrs-full:OrdinarySharesMember2023-09-300001769484biox:EquityCompensationPlanMember2023-09-300001769484biox:BankBorrowingsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484biox:BankBorrowingsMemberifrs-full:AtFairValueMember2023-09-300001769484biox:BankBorrowingsMember2023-09-300001769484biox:BankBorrowingsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484biox:BankBorrowingsMemberifrs-full:AtFairValueMember2023-06-300001769484biox:BankBorrowingsMember2023-06-300001769484ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember2022-07-012022-09-3000017694842033-09-3000017694842033-06-300001769484ifrs-full:AccumulatedImpairmentMember2023-09-300001769484biox:SeedsMember2023-09-300001769484biox:MicrobiologicalResaleProductsMember2023-09-300001769484biox:MicrobiologicalProductsProducedMember2023-09-300001769484ifrs-full:AccumulatedImpairmentMember2023-06-300001769484biox:SeedsMember2023-06-300001769484biox:MicrobiologicalResaleProductsMember2023-06-300001769484biox:MicrobiologicalProductsProducedMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:SoybeanHb4Member2023-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:RgRsOxWheatMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:MicrobiologyProductMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:EcoseedIntegratedProductsMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerSoftwareMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:SoybeanHb4Member2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:MicrobiologyProductMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:EcoseedIntegratedProductsMember2023-09-300001769484ifrs-full:GrossCarryingAmountMember2023-09-300001769484ifrs-full:CustomerrelatedIntangibleAssetsMember2023-09-300001769484ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2023-09-300001769484ifrs-full:ComputerSoftwareMember2023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-09-300001769484biox:SoybeanHb4Member2023-09-300001769484biox:RgRsOxWheatMember2023-09-300001769484biox:MicrobiologyProductMember2023-09-300001769484biox:EcoseedIntegratedProductsMember2023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberbiox:SoybeanHb4Member2023-06-300001769484ifrs-full:GrossCarryingAmountMemberbiox:RgRsOxWheatMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberbiox:MicrobiologyProductMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberbiox:EcoseedIntegratedProductsMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerSoftwareMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:SoybeanHb4Member2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:MicrobiologyProductMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:EcoseedIntegratedProductsMember2023-06-300001769484ifrs-full:GrossCarryingAmountMember2023-06-300001769484ifrs-full:CustomerrelatedIntangibleAssetsMember2023-06-300001769484ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2023-06-300001769484ifrs-full:ComputerSoftwareMember2023-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-06-300001769484biox:SoybeanHb4Member2023-06-300001769484biox:RgRsOxWheatMember2023-06-300001769484biox:MicrobiologyProductMember2023-06-300001769484biox:EcoseedIntegratedProductsMember2023-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:SoybeanHb4Member2022-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:RgRsOxWheatMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:MicrobiologyProductMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:EcoseedIntegratedProductsMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerSoftwareMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:SoybeanHb4Member2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:MicrobiologyProductMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:EcoseedIntegratedProductsMember2022-09-300001769484ifrs-full:GrossCarryingAmountMember2022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberbiox:SoybeanHb4Member2022-06-300001769484ifrs-full:GrossCarryingAmountMemberbiox:RgRsOxWheatMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberbiox:MicrobiologyProductMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberbiox:EcoseedIntegratedProductsMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerSoftwareMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:SoybeanHb4Member2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:MicrobiologyProductMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:EcoseedIntegratedProductsMember2022-06-300001769484ifrs-full:GrossCarryingAmountMember2022-06-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-06-300001769484ifrs-full:TreasurySharesMember2023-07-012023-09-300001769484ifrs-full:TreasurySharesMember2022-07-012022-09-300001769484ifrs-full:EquityAttributableToOwnersOfParentMember2023-07-012023-09-300001769484biox:StockOptionsAndShareBasedIncentivesMember2023-07-012023-09-300001769484biox:OwnSharesTradingPremiumMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:FixturesAndFittingsMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:LandAndBuildingsMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:EcoseedIntegratedProductsMember2023-07-012023-09-300001769484biox:RizobacterArgentinaMember2023-09-300001769484biox:ProFarmGroupInc.Member2023-09-300001769484biox:InsumosAgroqumicosMember2023-09-300001769484biox:BioceresCropsMember2023-09-300001769484biox:RizobacterArgentinaMember2023-06-300001769484biox:ProFarmGroupInc.Member2023-06-300001769484biox:InsumosAgroqumicosMember2023-06-300001769484biox:BioceresCropsMember2023-06-300001769484biox:BiologicalAssetsWheatMember2023-07-012023-09-300001769484biox:BiologicalAssetsBarleyMember2023-07-012023-09-300001769484ifrs-full:Level2OfFairValueHierarchyMember2023-09-300001769484ifrs-full:Level2OfFairValueHierarchyMember2023-06-300001769484ifrs-full:LeaseLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484ifrs-full:ContingentConsiderationMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484biox:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484biox:TradeAndOtherPayablesMemberifrs-full:AtFairValueMember2023-09-300001769484biox:ConvertibleNotesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484biox:BorrowingMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484ifrs-full:LeaseLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484ifrs-full:ContingentConsiderationMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484biox:TradeAndOtherPayablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484biox:TradeAndOtherPayablesMemberifrs-full:AtFairValueMember2023-06-300001769484biox:ConvertibleNotesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484biox:BorrowingMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484ifrs-full:InvestmentFundsMemberifrs-full:Level1OfFairValueHierarchyMember2023-09-300001769484biox:USTreasuryBillsMemberifrs-full:Level1OfFairValueHierarchyMember2023-09-300001769484biox:OtherInvestmentMemberifrs-full:Level1OfFairValueHierarchyMember2023-09-300001769484ifrs-full:InvestmentFundsMemberifrs-full:Level1OfFairValueHierarchyMember2023-06-300001769484biox:USTreasuryBillsMemberifrs-full:Level1OfFairValueHierarchyMember2023-06-300001769484biox:OtherInvestmentMemberifrs-full:Level1OfFairValueHierarchyMember2023-06-300001769484ifrs-full:TradeReceivablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484biox:OtherReceivablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484biox:OtherFinancialAssetsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484biox:OtherFinancialAssetsMemberifrs-full:AtFairValueMember2023-09-300001769484biox:CashAndEquivalentsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484biox:CashAndEquivalentsMemberifrs-full:AtFairValueMember2023-09-300001769484ifrs-full:TradeReceivablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484biox:OtherReceivablesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484biox:OtherFinancialAssetsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484biox:OtherFinancialAssetsMemberifrs-full:AtFairValueMember2023-06-300001769484biox:CashAndEquivalentsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484ifrs-full:TopOfRangeMemberbiox:PastShareOptionPlanMember2023-08-012023-08-310001769484ifrs-full:BottomOfRangeMemberbiox:PastShareOptionPlanMember2023-08-012023-08-310001769484biox:PerformanceShareOptionPlanMember2023-08-012023-08-310001769484biox:BaseShareOptionPlanMember2023-08-012023-08-310001769484ifrs-full:TreasurySharesMember2023-09-300001769484ifrs-full:SharePremiumMember2023-09-300001769484ifrs-full:RetainedEarningsMember2023-09-300001769484ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-09-300001769484ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember2023-09-300001769484ifrs-full:NoncontrollingInterestsMember2023-09-300001769484ifrs-full:IssuedCapitalMember2023-09-300001769484ifrs-full:EquityAttributableToOwnersOfParentMember2023-09-300001769484biox:StockOptionsAndShareBasedIncentivesMember2023-09-300001769484biox:RevaluationOfPropertyPlantAndEquipmentAndEffectOfTaxRateChangeMember2023-09-300001769484biox:OwnSharesTradingPremiumMember2023-09-300001769484biox:ChangesInNonControllingInterestMember2023-09-300001769484ifrs-full:TreasurySharesMember2023-06-300001769484ifrs-full:SharePremiumMember2023-06-300001769484ifrs-full:RetainedEarningsMember2023-06-300001769484ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-06-300001769484ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember2023-06-300001769484ifrs-full:NoncontrollingInterestsMember2023-06-300001769484ifrs-full:IssuedCapitalMember2023-06-300001769484ifrs-full:EquityAttributableToOwnersOfParentMember2023-06-300001769484biox:StockOptionsAndShareBasedIncentivesMember2023-06-300001769484biox:RevaluationOfPropertyPlantAndEquipmentAndEffectOfTaxRateChangeMember2023-06-300001769484biox:OwnSharesTradingPremiumMember2023-06-300001769484biox:ChangesInNonControllingInterestMember2023-06-300001769484ifrs-full:TreasurySharesMember2022-09-300001769484ifrs-full:SharePremiumMember2022-09-300001769484ifrs-full:RetainedEarningsMember2022-09-300001769484ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-09-300001769484ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember2022-09-300001769484ifrs-full:NoncontrollingInterestsMember2022-09-300001769484ifrs-full:IssuedCapitalMember2022-09-300001769484ifrs-full:EquityAttributableToOwnersOfParentMember2022-09-300001769484biox:StockOptionsAndShareBasedIncentivesMember2022-09-300001769484biox:RevaluationOfPropertyPlantAndEquipmentAndEffectOfTaxRateChangeMember2022-09-300001769484biox:OwnSharesTradingPremiumMember2022-09-300001769484biox:ChangesInNonControllingInterestMember2022-09-300001769484ifrs-full:TreasurySharesMember2022-06-300001769484ifrs-full:SharePremiumMember2022-06-300001769484ifrs-full:RetainedEarningsMember2022-06-300001769484ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-06-300001769484ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember2022-06-300001769484ifrs-full:NoncontrollingInterestsMember2022-06-300001769484ifrs-full:IssuedCapitalMember2022-06-300001769484ifrs-full:EquityAttributableToOwnersOfParentMember2022-06-300001769484biox:StockOptionsAndShareBasedIncentivesMember2022-06-300001769484biox:RevaluationOfPropertyPlantAndEquipmentAndEffectOfTaxRateChangeMember2022-06-300001769484biox:OwnSharesTradingPremiumMember2022-06-300001769484biox:ChangesInNonControllingInterestMember2022-06-300001769484ifrs-full:NoncontrollingInterestsMember2022-07-012022-09-300001769484biox:JointVenturesAndAssociatesMember2023-09-300001769484biox:JointVenturesAndAssociatesMember2023-06-300001769484biox:SecuredGuaranteedNotesMemberifrs-full:AtFairValueMember2033-09-300001769484biox:SecuredGuaranteedNotesMemberifrs-full:AtCostMember2033-09-300001769484biox:SecuredConvertibleGuaranteedNotesMemberifrs-full:AtFairValueMember2033-09-300001769484biox:SecuredConvertibleGuaranteedNotesMemberifrs-full:AtCostMember2033-09-300001769484ifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-09-300001769484ifrs-full:AtFairValueMember2023-09-300001769484ifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-06-300001769484ifrs-full:AtFairValueMember2023-06-300001769484biox:SunflowerMember2023-09-300001769484biox:BiologicalAssetsWheatMember2023-09-300001769484biox:BiologicalAssetsSoybeanMember2023-09-300001769484biox:BiologicalAssetsCornMember2023-09-300001769484biox:BiologicalAssetsBarleyMember2023-09-300001769484biox:SunflowerMember2023-06-300001769484biox:BiologicalAssetsWheatMember2023-06-300001769484biox:BiologicalAssetsSoybeanMember2023-06-300001769484biox:BiologicalAssetsCornMember2023-06-300001769484biox:BiologicalAssetsBarleyMember2023-06-300001769484biox:BiologicalAssetsWheatMember2022-09-300001769484biox:BiologicalAssetsBarleyMember2022-09-300001769484biox:BiologicalAssetsWheatMember2022-06-300001769484biox:BiologicalAssetsBarleyMember2022-06-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:VehiclesMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:MachineryMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:FixturesAndFittingsMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerEquipmentMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:SoybeanHb4Member2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:MicrobiologyProductMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerSoftwareMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:SoybeanHb4Member2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:MicrobiologyProductMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:EcoseedIntegratedProductsMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:ComputerSoftwareMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:SoybeanHb4Member2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerSoftwareMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:SoybeanHb4Member2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:MicrobiologyProductMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberbiox:EcoseedIntegratedProductsMember2022-07-012022-09-300001769484biox:SunflowerMember2023-07-012023-09-300001769484biox:BiologicalAssetsSoybeanMember2023-07-012023-09-300001769484biox:BiologicalAssetsCornMember2023-07-012023-09-300001769484biox:BiologicalAssetsWheatMember2022-07-012022-09-300001769484biox:BiologicalAssetsBarleyMember2022-07-012022-09-300001769484ifrs-full:MachineryMember2022-07-012022-09-300001769484ifrs-full:LandAndBuildingsMember2022-07-012022-09-300001769484ifrs-full:FixturesAndFittingsMember2022-07-012022-09-300001769484ifrs-full:ConstructionInProgressMember2022-07-012022-09-300001769484ifrs-full:ComputerEquipmentMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMemberbiox:MicrobiologyProductMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMember2022-07-012022-09-300001769484ifrs-full:OtherRelatedPartiesMember2023-09-300001769484ifrs-full:JointVenturesWhereEntityIsVenturerMember2023-09-300001769484ifrs-full:JointVenturesWhereEntityIsVenturerMember2023-06-300001769484biox:PerformanceShareOptionPlanMemberbiox:IfEbitdaReachesAtLeastUs150MillionMember2023-08-012023-08-310001769484ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2023-07-012023-09-300001769484ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2022-07-012022-09-300001769484ifrs-full:JointVenturesWhereEntityIsVenturerMember2023-07-012023-09-300001769484ifrs-full:JointVenturesWhereEntityIsVenturerMember2022-07-012022-09-300001769484biox:SeedAndIntegratedProductsMember2023-07-012023-09-300001769484biox:CropProtectionMember2023-07-012023-09-300001769484biox:CropNutritionMember2023-07-012023-09-300001769484biox:SeedAndIntegratedProductsMember2022-07-012022-09-300001769484biox:CropProtectionMember2022-07-012022-09-300001769484biox:CropNutritionMember2022-07-012022-09-300001769484ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2023-09-300001769484ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2023-06-300001769484biox:ParentCompaniesAndRelatedPartiesToParentMember2023-09-300001769484biox:ParentCompaniesAndRelatedPartiesToParentMember2023-06-300001769484biox:TrigallGeneticsS.a.Member2023-09-300001769484biox:TrigallGeneticsS.a.Member2023-06-300001769484biox:SynertechIndustriasS.aMember2023-09-300001769484biox:MoolecScienceS.a.Member2023-09-300001769484biox:AlfalfaTechnologiesS.r.lMember2023-09-300001769484biox:SynertechIndustriasS.aMember2023-06-300001769484biox:MoolecScienceS.a.Member2023-06-300001769484biox:AlfalfaTechnologiesS.r.lMember2023-06-300001769484ifrs-full:OtherRelatedPartiesMember2022-07-012022-09-3000017694842022-09-3000017694842022-06-300001769484ifrs-full:OtherRelatedPartiesMember2023-07-012023-09-300001769484biox:ParentCompaniesAndRelatedPartiesToParentMember2023-07-012023-09-300001769484biox:ParentCompaniesAndRelatedPartiesToParentMember2022-07-012022-09-300001769484ifrs-full:SharePremiumMember2022-07-012022-09-300001769484ifrs-full:IssuedCapitalMember2022-07-012022-09-300001769484ifrs-full:EquityAttributableToOwnersOfParentMember2022-07-012022-09-300001769484biox:StockOptionsAndShareBasedIncentivesMember2022-07-012022-09-300001769484ifrs-full:TopOfRangeMemberbiox:PerformanceShareOptionPlanMemberbiox:IfEbitdaReachesAtLeastUs150MillionMember2023-08-012023-08-310001769484biox:PerformanceShareOptionPlanMemberbiox:IfEbitdaReachesAtLeastUs120MillionMember2023-08-012023-08-310001769484biox:IfrsResearchAndDevelopmentExpenseMember2023-07-012023-09-300001769484ifrs-full:CurrencyRiskMember2023-07-012023-09-300001769484ifrs-full:GrossCarryingAmountMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-07-012023-06-300001769484biox:IfrsResearchAndDevelopmentExpenseMember2022-07-012022-09-300001769484ifrs-full:SellingGeneralAndAdministrativeExpenseMember2023-07-012023-09-3000017694842023-09-3000017694842023-06-300001769484ifrs-full:CostOfSalesMember2023-07-012023-09-300001769484biox:ProductionCostAndSellingGeneralAndAdministrativeExpenseMember2023-07-012023-09-300001769484ifrs-full:SellingGeneralAndAdministrativeExpenseMember2022-07-012022-09-300001769484ifrs-full:CostOfSalesMember2022-07-012022-09-300001769484biox:ProductionCostAndSellingGeneralAndAdministrativeExpenseMember2022-07-012022-09-3000017694842022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:VehiclesMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OfficeEquipmentMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:MachineryMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:FixturesAndFittingsMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerEquipmentMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-07-012023-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:VehiclesMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OfficeEquipmentMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:MachineryMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:FixturesAndFittingsMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:ComputerEquipmentMember2022-07-012022-09-300001769484ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-07-012022-09-300001769484ifrs-full:GrossCarryingAmountMember2022-07-012023-06-3000017694842022-07-012023-06-30iso4217:USDbiox:itemxbrli:purebiox:countrybiox:categorybiox:Votexbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rules 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of November 2023

Commission File Number: 001-38836

BIOCERES CROP SOLUTIONS CORP.

(Translation of registrant’s name into English)

Ocampo 210 bis, Predio CCT, Rosario

Province of Santa Fe, Argentina

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒                                                             Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXPLANATORY NOTE

This Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (Registration No. 333-272280) and Form S-8 (Registration Nos. 333-255635, 333-266333 and 333-271941), and the following exhibit is filed as part of this Form 6-K:

Exhibit List

Exhibit No.

    

Description

99.1

Bioceres Crop Solutions Corp. unaudited interim condensed consolidated financial statements as of September 30, 2023 and June 30, 2023, and for the three -month periods ended September 30, 2023 and 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIOCERES CROP SOLUTIONS CORP.

(Registrant)

Dated: November 29, 2023

By:

/s/ Federico Trucco

Name:

Federico Trucco

Title:

Chief Executive Officer

628499970

Table of Contents

Exhibit 99.1

Graphic

BIOCERES CROP SOLUTIONS CORP.

Unaudited interim condensed consolidated financial statements
as of September 30, 2023 and June 30, 2023,

and for the three-month periods ended

September 30, 2023 and 2022. 

Table of Contents

Graphic

INDEX

Unaudited interim condensed consolidated financial statements as of September 30, 2023 and June 30, 2023, and for the three-month periods ended September 30, 2023 and 2022.

Unaudited interim condensed consolidated statements of financial position as of September 30, 2023 and June 30, 2023.

F-3

Unaudited interim condensed consolidated statements of comprehensive income for the three-month periods ended September 30, 2023 and 2022.

F-5

Unaudited interim condensed consolidated statements of changes in equity for the three-month periods ended September 30, 2023 and 2022.

F-6

Unaudited interim condensed consolidated statements of cash flows for the three-month periods ended September 30, 2023 and 2022.

F-8

Notes to the unaudited interim condensed consolidated financial statements

F-11

F-2

Table of Contents

Graphic

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

As of September 30, 2023, and June 30, 2023

(Amounts in US$)

    

Notes

    

09/30/2023

    

06/30/2023

ASSETS

 

  

 

  

 

  

CURRENT ASSETS

 

  

 

  

 

  

Cash and cash equivalents

 

5.1

 

28,373,924

 

48,129,194

Other financial assets

 

5.2

 

14,628,202

 

12,135,020

Trade receivables

 

5.3

 

186,276,319

 

158,006,474

Other receivables

 

5.4

 

24,902,503

 

28,824,998

Income and minimum presumed recoverable income taxes

 

2,022,328

 

9,444,898

Inventories

 

5.5

 

138,076,822

 

140,426,975

Biological assets

5.6

1,141,113

146,842

Total current assets

 

395,421,211

 

397,114,401

NON-CURRENT ASSETS

 

 

Other financial assets

 

5.2

 

502,910

 

444,909

Other receivables

5.4

2,393,939

2,546,241

Income and minimum presumed recoverable income taxes

 

 

5,446

 

16,286

Deferred tax assets

7

 

8,230,402

 

7,312,964

Investments in joint ventures and associates

11

 

40,820,784

 

39,296,810

Investment properties

 

5.10

 

3,675,493

 

3,589,749

Property, plant and equipment

 

5.7

 

69,930,709

 

67,853,835

Intangible assets

 

5.8

 

173,034,536

 

173,783,956

Goodwill

 

5.9

 

112,163,432

 

112,163,432

Right of use asset

14

13,519,199

13,936,575

Total non-current assets

 

  

 

424,276,850

 

420,944,757

Total assets

 

  

 

819,698,061

 

818,059,158

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

F-3

Table of Contents

Graphic

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

As of September 30, 2023, and June 30, 2023

(Amounts in US$)

LIABILITIES

    

Notes

    

09/30/2023

06/30/2023

 

  

 

  

 

  

CURRENT LIABILITIES

 

 

 

Trade and other payables

 

5.11

 

159,125,358

 

150,807,674

Borrowings

 

5.12

 

100,720,985

 

107,639,659

Employee benefits and social security

 

5.14

 

10,019,165

 

9,606,707

Deferred revenue and advances from customers

5.15

 

32,771,902

 

24,875,662

Income tax payable

 

 

536,840

 

509,034

Consideration for acquisition

4,202,389

1,415,099

Lease liabilities

14

 

4,326,889

 

3,858,699

Total current liabilities

311,703,528

298,712,534

 

 

NON-CURRENT LIABILITIES

Borrowings

5.12

48,789,492

60,670,946

Deferred revenue and advances from customers

5.15

2,202,374

2,057,805

Joint ventures and associates

11

 

638,126

 

622,823

Deferred tax liabilities

 

7

 

34,393,580

 

35,785,347

Provisions

 

 

668,775

 

891,769

Consideration for acquisition

2,540,181

3,578,157

Secured notes

5.13

76,911,874

75,213,146

Lease liabilities

14

9,225,862

10,030,524

Total non-current liabilities

 

175,370,264

 

188,850,517

Total liabilities

 

  

 

487,073,792

 

487,563,051

EQUITY

 

  

 

 

Equity attributable to owners of the parent

 

  

 

298,966,341

298,594,088

Non-controlling interest

 

  

 

33,657,928

31,902,019

Total equity

 

  

 

332,624,269

330,496,107

Total equity and liabilities

 

  

 

819,698,061

 

818,059,158

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

F-4

Table of Contents

Graphic

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the three-month periods ended of September 30, 2023, and 2022

(Amounts in US$)

    

Notes

    

09/30/2023

09/30/2022

Revenues from contracts with customers

 

6.1

 

116,182,805

126,843,248

Initial recognition and changes in the fair value of biological assets at the point of harvest

 

 

410,913

490,006

Cost of sales

6.2

(71,615,781)

(75,675,878)

Changes in the net realizable value of agricultural products after harvest

 

 

(1,446,316)

(227,936)

Research and development expenses

 

6.3

 

(4,581,241)

(3,852,014)

Selling, general and administrative expenses

 

6.4

 

(33,932,848)

(31,904,911)

Share of profit or loss of joint ventures and associates

 

11

 

1,508,671

842,240

Other income or expenses, net

6.5

 

(1,231,635)

478,041

Operating profit

 

5,294,568

16,992,796

 

 

 

Financial cost

6.6

 

(7,661,857)

(6,779,847)

Other financial results

6.6

117,865

(1,288,306)

(Loss) profit before income tax

 

(2,249,424)

8,924,643

Income tax

7

(429,040)

(5,012,643)

(Loss) profit for the period

 

(2,678,464)

3,912,000

(Loss) profit for the period attributable to:

 

  

 

  

Equity holders of the parent

 

(4,591,634)

498,297

Non-controlling interests

 

1,913,170

3,413,703

 

(2,678,464)

3,912,000

(Loss) profit per share

Basic (loss) profit attributable to ordinary equity holders of the parent

8

(0.0731)

0.0082

Diluted (loss) profit attributable to ordinary equity holders of the parent

8

(0.0731)

0.0081

(Loss) profit for the period

(2,678,464)

3,912,000

Other comprehensive (loss) income

(929,957)

31,025

Items that may be subsequently reclassified to profit and loss

(929,957)

31,025

Foreign exchange differences on translation of foreign operations from joint ventures

100,868

Foreign exchange differences on translation of foreign operations

(929,957)

(69,843)

Total comprehensive (loss) profit

(3,608,421)

3,943,025

Total comprehensive (loss) profit attributable to:

Equity holders of the parent

(5,364,330)

401,715

Non-controlling interests

1,755,909

3,541,310

(3,608,421)

3,943,025

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

F-5

Table of Contents

Graphic

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

For the three-month periods ended of September 30, 2023, and 2022

(Amounts in US$)

Attributable to the equity holders of the parent

Equity /

 

 

 

 

Stock

 

 

 

Revaluation

(deficit)

Changes in

Own

 

options

 

 

Cost of

Foreign

of PP&E

attributable

non-

shares

 

and share

 

 

own

currency

and effect

to owners

Non-

Issued

Share

controlling

trading

based

Convertible

 

shares

Retained

translation

of tax rate

of the

controlling

Total

Description

    

capital

    

premium

    

interests

    

premium

    

incentives

    

instruments

    

held

    

deficit

    

reserve

    

change

    

parent

    

Interests

equity

06/30/2022

4,637

158,819,506

(255,893)

(916,202)

3,767,925

175,745

(3,530,926)

(32,682,893)

969,402

1,007,272

127,358,573

30,940,275

    

158,298,848

Share-based incentives

6

554,999

135,361

55,892

746,258

746,258

Business combination

1,640

153,357,564

1,620,140

154,979,344

154,979,344

Capitalization of convertible notes (Note 5.13)

153

12,211,485

12,211,638

12,211,638

Purchase of own shares

(24,291,047)

(24,291,047)

(24,291,047)

Issuance of convertible notes (Note 7.13)

9,109,516

9,109,516

9,109,516

Distribution of dividends by subsidiary

(187,977)

(187,977)

(Loss) profit for the period

498,297

498,297

3,413,703

3,912,000

Other comprehensive income (loss)

(96,582)

(96,582)

127,607

31,025

09/30/2022

 

6,436

 

324,943,554

 

(255,893)

 

(780,841)

 

5,443,957

 

9,285,261

 

(27,821,973)

 

(32,184,596)

872,820

1,007,272

280,515,997

34,293,608

314,809,605

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

F-6

Table of Contents

Graphic

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

For the three-month periods ended of September 30, 2023, and 2022

(Amounts in US$)

Attributable to the equity holders of the parent

Stock

Revaluation

Equity /

Changes

Own

 options

Cost of

Foreign

 of PP&E

(deficit)

in non-

shares

and share

own

currency

and effect

attributable

Non-

Issued

Share

controlling

trading

based

Convertible

shares

Retained

translation

of tax rate

to owners of

controlling

Total

Description

    

 capital

    

 premium

    

interests

    

premium

    

incentives

    

instruments

    

held

    

deficit

    

reserve

    

change

    

the parent

    

Interests

    

equity

06/30/2023

6,493

327,028,559

(255,893)

(780,841)

6,645,442

9,285,261

(30,553,591)

(13,903,017)

1,282,377

(160,702)

298,594,088

31,902,019

    

330,496,107

Share-based incentives

6,193,668

6,193,668

6,193,668

Purchase of own shares

(457,085)

(457,085)

(457,085)

(Loss) profit for the period

(4,591,634)

(4,591,634)

1,913,170

(2,678,464)

Other comprehensive loss

(772,696)

(772,696)

(157,261)

(929,957)

09/30/2023

 

6,493

 

327,028,559

 

(255,893)

 

(780,841)

 

12,839,110

 

9,285,261

 

(31,010,676)

 

(18,494,651)

509,681

(160,702)

298,966,341

33,657,928

332,624,269

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

F-7

Table of Contents

Graphic

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the three-month periods ended of September 30, 2023, and 2022

(Amounts in US$)

    

Notes

    

09/30/2023

    

09/30/2022

OPERATING ACTIVITIES

 

 

 

(Loss) profit for the period

 

 

(2,678,464)

 

3,912,000

Adjustments to reconcile profit to net cash flows

 

 

 

Income tax

 

7

 

429,040

 

5,012,643

Financial results

 

 

7,543,992

 

8,068,153

Depreciation of property, plant and equipment

 

5.7

 

1,243,403

 

1,382,093

Amortization of intangible assets

 

5.8

 

2,747,206

 

2,476,832

Depreciation of leased assets

 

14

 

837,199

676,427

Transactional expenses

2,794,339

Share-based incentive and stock options

 

 

6,193,668

 

227,351

Share of profit or loss of joint ventures and associates

 

11

 

(1,508,671)

 

(842,240)

Provisions for contingencies

 

27,109

 

2,448

Allowance for impairment of trade debtors

 

 

352,920

 

156,053

Allowance for obsolescence

 

 

505,285

 

618,489

Initial recognition and changes in the fair value of biological assets

 

 

(410,913)

 

(490,006)

Changes in the net realizable value of agricultural products after harvest

1,446,316

227,936

Gain or loss on sale of equipment and intangible assets

 

 

(26,669)

 

(115,942)

Working capital adjustments

 

 

 

Trade receivables

 

 

(31,012,196)

 

(29,709,414)

Other receivables

 

 

3,722,853

 

(5,665,708)

Income and minimum presumed income taxes payable

 

 

7,113,764

 

(376,576)

Inventories and biological assets

 

 

(197,454)

 

(7,391,556)

Trade and other payables

 

 

7,499,929

 

(18,108,556)

Employee benefits and social security

 

 

412,458

 

3,226,505

Deferred revenue and advances from customers

 

 

8,040,809

 

373,181

Income taxes paid

(163,205)

(1,051,644)

Interest collected

 

 

2,293,676

2,125,194

Inflation effects on working capital adjustments

 

 

321,539

69,662

Net cash flows generated (used) by operating activities

 

 

14,733,594

(32,402,336)

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

F-8

Table of Contents

Graphic

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the three-month periods ended of September 30, 2023, and 2022

(Amounts in US$)

    

Notes

    

09/30/2023

    

09/30/2022

INVESTMENT ACTIVITIES

 

  

 

  

 

  

Proceeds from sale of property, plant and equipment

 

35,682

 

115,942

Net cash received from business combination

5,933,265

Net loans granted to shareholders and other related parties

1,609

Proceeds from financial assets

(509,534)

2,729,598

Investment in financial assets

(2,215,965)

(889,342)

Purchase of property, plant and equipment

 

5.7

 

(3,985,249)

 

(1,414,730)

Capitalized development expenditures

 

5.8

 

(1,947,504)

 

(3,241,008)

Purchase of intangible assets

 

5.8

 

(64,486)

 

(209,863)

Net cash flows (used) generated by investing activities

 

(8,687,056)

 

3,025,471

FINANCING ACTIVITIES

 

  

 

  

Proceeds from borrowings

 

26,837,346

 

93,327,748

Repayment of borrowings and financed payments

 

(46,865,499)

 

(47,061,271)

Interest payments

 

(4,539,455)

 

(3,016,078)

Other financial proceeds or payments, net

 

(781,199)

 

(1,717,070)

Purchase of own shares

(457,085)

(376,018)

Leased assets payments

14

(1,170,039)

(744,365)

Cash dividend distributed by subsidiary

(187,977)

Net cash flows (used) generated by financing activities

 

(26,975,931)

 

40,224,969

Net (decrease) increase in cash and cash equivalents

 

(20,929,393)

 

10,848,104

Inflation effects on cash and cash equivalents

(24,266)

(12,404)

Cash and cash equivalents as of beginning of the period

 

5.1

 

48,129,194

 

33,475,266

Effect of exchange rate changes on cash and equivalents

 

1,198,389

 

3,076,600

Cash and cash equivalents as of the end of the period

 

5.1

 

28,373,924

 

47,387,566

The accompanying Notes are an integral part of these unaudited interim condensed consolidated financial statements. Related parties’ balances and transactions are disclosed in Note 15.

F-9

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

Index

1.

General information.

2.

Accounting standards and basis of preparation.

3.

New standards, amendments and interpretations issued by the IASB.

4.

Seasonality

5.

Information about components of unaudited interim condensed consolidated statement of financial position.

6.

Information about components of unaudited interim condensed consolidated statement of comprehensive income.

7.

Taxation.

8.

Earnings per share.

9.

Equity information.

10.

Cash flow information.

11.

Joint ventures and associates.

12.

Segment information.

13.

Financial instruments – Risk management.

14.

Leases.

15.

Shareholders and other related parties’ balances and transactions.

16.

Key management personnel compensation.

17.

Share-based payments.

18.

Contingencies, commitments and restrictions on the distribution of profits.

19.

Events occurring after the reporting period.

F-10

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

1.    GENERAL INFORMATION

Bioceres Crop Solutions Corp. (NASDAQ:BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres’ products create economic incentives for farmers and other stakeholders to adopt environmentally friendly production practices. Bioceres has a unique biotech platform with high impact, patented technologies for seeds and microbial ag inputs, as well as next generation crop nutrition and protection solutions.

Bioceres is a global company with an extensive geographic footprint. The Group’s agricultural inputs are marketed across more than 40 countries, mainly in Argentina, Brazil, United States, Europe and South Africa.

Unless the context otherwise requires, “we”, “us”, “our”, “Bioceres”, “BIOX”, “the Group”, and “Bioceres Crop Solutions” will refer to Bioceres Crop Solutions Corp. and its subsidiaries.

2.    ACCOUNTING STANDARDS AND BASIS OF PREPARATION

Statement of compliance with IFRS as issued by IASB

These unaudited interim condensed consolidated financial statements for the three-month period ended September 30, 2023, have been prepared in accordance with Accounting Standard IAS 34 Interim Financial Reporting.

These unaudited interim condensed consolidated financial statements do not include all notes of the type normally included in an annual financial statement. Accordingly, these unaudited interim condensed consolidated financial statements are to be read in conjunction with the consolidated financial statements for the fiscal year ended June 30, 2023.

Authorization for the issue of the consolidated financial statements

These unaudited interim condensed consolidated financial statements of the Group as of September 30, 2023, June 30, 2023 and for the three-month periods ended September 30, 2023 and 2022 were authorized by the Board of Directors of Bioceres Crop Solutions Corp. on November 29, 2023.

Basis of measurement

The consolidated financial statements of the Group have been prepared using:

Going concern basis of accounting, considering the conclusion of the assessment made by the Group’s Management about the ability of the Group and its subsidiaries to continue as a going concern, in accordance with the requirements of paragraph 25 of IAS 1, “Presentation of Financial Statements”.
Accrual basis of accounting (except for cash flows information). Under this basis of accounting, the effects of transactions and other events are recognized as they occur, even when there are no cash flows.

Functional currency and presentation currency

a)

Functional currency

Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary economic market in which the entity operates (i.e., “the functional currency”).

F-11

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

b)

Presentation currency

The consolidated financial statements of the Group are presented in US dollars.

c)

Foreign currency

Transactions entered into by Group entities in a currency other than their functional currency are recorded at the relevant exchange rates as of the date upon which such transactions occur. Foreign currency monetary assets and liabilities are translated at the prevailing exchanges rates as of the final day of each reporting period. Exchange differences arising from the retranslation of unsettled monetary assets and liabilities are recognized immediately in profit or loss, except for foreign currency borrowings qualifying as a hedge of a net investment in a foreign operation for which exchange differences are recognized in other comprehensive income and accumulated in the foreign exchange reserve along with the exchange differences arising from the retranslation of the foreign operation. Upon the disposal of a foreign operation, the cumulative exchange differences recognized in the foreign exchange reserve relating to such operation up to the date of disposal are transferred to the consolidated statement of profit or loss and other comprehensive income as part of the gain or loss recognized upon such disposal.

Changes in accounting policies

The accounting policies adopted in the preparation of these unaudited interim condensed consolidated financial statements are consistent with those adopted for the preparation of the consolidated financial statements as of June 30, 2023.

3.    NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS ISSUED BY THE IASB

a)The following new standards, amendments and interpretations became applicable for the current reporting period and adopted by the Group.

- Amendment to IAS 12 –Deferred tax related to assets and liabilities arising from a single transaction.
- International Tax Reform—Pillar Two Model Rules (Amendments to IAS 12)
- Amendments to IAS 1 and IFRS Practice Statement 2- Disclosure of Accounting Policies
- Amendments to IAS 8-Definition of Accounting Estimates
- IFRS 17, “Insurance Contracts”

These new standards and amendments did not have any material impact on the Group.

b)The following new standards are not yet adopted by the Group.

- Amendments to IFRS 16- Lease Liability in a Sale and Leaseback. The amendments are effective for annual reporting periods beginning on or after 1 January 2024.
- Amendments to IAS1 – Non- current liabilities with covenants. The amendments are effective for annual reporting periods beginning on or after 1 January 2024.
- Amendments to IAS 7- Statement of Cash Flows & to IFRS 7- Financial Instruments: Disclosures. The amendments are effective for annual reporting periods beginning on or after 1 January 2024.
- Amendments to IAS 21- The Effects of Changes in Foreign Exchange Ratestitled Lack of Exchangeability. The amendments are effective for annual reporting periods beginning on or after 1 January 2025.
- Amendment to IAS 7 and IFRS 7 - Supplier Financing. The amendments are effective for annual periods beginning on or after January 1, 2024.

These amendments are not expected to have material impact on the Group.

F-12

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

4.    SEASONALITY

Our revenues fluctuate depending on the timing of orders from our distributors and customers and on prevailing market prices, which influence the purchase decisions of growers, the end users of our seed and integrated products, crop protection products and crop nutrition products. Given the cyclicality of crop planting and harvesting, as well as growing seasons, which vary from year to year, our business is highly seasonal. This results in substantial fluctuations in quarterly sales and profitability. Our portfolio is highly oriented to crop planting. Generally, our sales are concentrated in the third and fourth quarters of each calendar year, when demand for our seed and integrated products, crop protection products and crop nutrition products increases as growers begin planting their summer crops in South America, while winter crop season occurs in the Northern hemisphere. With our seed and integrated products business, we contract with growers and seed suppliers based upon our anticipated market demand. Generally, in our seed and integrated products business we stock the seed during the harvest season and ship from inventory throughout the year, with the objective of selling most of the inventory from the current year’s harvest before the next year’s, with our crop protection and our crop nutrition business following a similar cycle to the seed cycle. Milestone, royalty, and license revenues are also likely to fluctuate from period to period given the seasonality of agriculture and time required to progress from one milestone to the next.

Our seed and integrated products, crop protection and crop nutrition businesses are also affected by unpredictable weather conditions such as heavy rains, hail, floods, freezing conditions, windstorms, drought or fire, as well as other hazardous situations beyond our control, which may cause our sales and operating results to fluctuate significantly. In addition, disruptions that cause delays by growers in harvesting or planting can result in the movement of orders to a future quarter, which also causes fluctuations in our quarterly operating results. Finally, some of our customers and distributors order in bulk only one or two times a year, which may further cause our seed product revenues to fluctuate from period to period.

5.    INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

5.1.  Cash and cash equivalents

    

09/30/2023

    

06/30/2023

Cash at bank and on hand

25,954,730

48,129,194

Mutual funds

2,419,194

 

28,373,924

48,129,194

5.2.  Other financial assets

    

09/30/2023

    

06/30/2023

Current

 

 

  

Restricted short-term deposits

 

 

212,703

US Treasury bills

9,719,486

9,163,298

Mutual funds

3,236,702

1,596,539

Other investments

 

1,672,014

 

1,162,480

 

14,628,202

 

12,135,020

 

09/30/2023

 

06/30/2023

Non-current

 

  

 

  

Shares of Bioceres S.A.

 

444,575

 

444,635

Other investments

 

58,335

 

274

 

502,910

 

444,909

F-13

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

5.3.  Trade receivables

    

09/30/2023

    

06/30/2023

Current

Trade debtors

189,222,562

160,269,233

Allowance for impairment of trade debtors

 

(7,615,433)

 

(7,425,604)

Shareholders and other related parties (Note 15)

 

1,368,373

 

Allowance for credit notes to be issued

 

(2,610,596)

 

(3,694,019)

Trade debtors - Joint ventures and associates (Note 15)

 

781,451

 

865,627

Deferred checks

 

5,129,962

 

7,991,237

186,276,319

 

158,006,474

The book value is reasonably approximate to the fair value given its short-term nature.

5.4.  Other receivables

    

09/30/2023

    

06/30/2023

Current

 

  

 

  

Taxes

 

6,009,626

 

6,113,764

Receivables for PP&E sales

89,715

156,423

Shareholders and other related parties (Note 15)

 

2,919,431

 

3,792,429

Other receivables - Joint ventures and associates (Note 15)

 

6,469,863

 

6,104,219

Prepayments to suppliers

 

5,010,022

 

10,956,831

Reimbursements over exports

 

10,558

 

10,558

Prepaid expenses and other receivables

 

3,657,633

 

1,302,221

Miscellaneous

 

735,655

 

388,553

 

24,902,503

 

28,824,998

    

09/30/2023

    

06/30/2023

Non-current

 

 

Taxes

 

865,588

 

873,699

Reimbursements over exports

 

1,268,928

 

1,290,227

Loans receivables

 

230,000

 

230,000

Miscellaneous

 

29,423

 

152,315

 

2,393,939

 

2,546,241

F-14

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

5.5.  Inventories

    

09/30/2023

    

06/30/2023

Seeds

 

9,293,210

1,542,159

Resale products

 

71,973,203

58,544,931

Manufactured products

 

19,604,930

25,881,761

Goods in transit

 

2,298,136

3,620,606

Supplies

 

18,709,303

24,893,187

Agricultural products

 

19,111,345

28,436,830

Allowance for obsolescence

 

(2,913,305)

(2,492,499)

138,076,822

140,426,975

Net of agricultural products

 

118,965,477

 

111,990,145

5.6.  Biological assets

Changes in Biological assets:

    

Soybean

Corn

    

Wheat

    

Barley

    

Sunflower

    

Total

Beginning of the period

87,785

59,057

146,842

Initial recognition and changes in the fair value of biological assets at the point of harvest

 

 

 

276,511

 

134,402

 

 

410,913

Costs incurred during the period

 

374,456

 

177,601

 

 

 

31,301

 

583,358

Period ended September 30, 2023

 

374,456

 

177,601

 

364,296

 

193,459

 

31,301

 

1,141,113

    

Wheat

    

Barley

    

Total

Beginning of the period

 

44,413

12,900

57,313

Initial recognition and changes in the fair value of biological assets at the point of harvest

 

365,833

 

124,173

 

490,006

Costs incurred during the period

 

378,631

 

122,837

 

501,468

Exchange differences

 

(16,699)

 

(5,344)

 

(22,043)

Period ended September 30, 2022

 

772,178

 

254,566

 

1,026,744

5.7.  Property, plant and equipment

Property, plant and equipment as of September 30, 2023 and June 30, 2023 included the following:

    

09/30/2023

    

06/30/2023

Gross carrying amount

 

96,833,359

 

93,634,779

Accumulated depreciation

 

(26,902,650)

 

(25,780,944)

Net carrying amount

 

69,930,709

 

67,853,835

F-15

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

Net carrying amount for each class of assets is as follows:

Net carrying

Net carrying

amount

 amount

Class

    

09/30/2023

    

06/30/2023

Office equipment

280,905

263,892

Vehicles

1,862,542

2,032,853

Equipment and computer software

 

167,741

 

174,399

Fixtures and fittings

 

2,676,861

 

2,862,949

Machinery and equipment

 

13,970,593

 

14,463,756

Land and buildings

 

35,640,076

 

36,144,792

Buildings in progress

 

15,331,991

 

11,911,194

Total

 

69,930,709

 

67,853,835

1.      Gross carrying amount as of September 30, 2023 is as follows:

Gross carrying amount

As of the

beginning

Foreign

As of the

of the

currency

end of the

Class

    

period

    

Additions

    

Disposals

    

translation

    

period

Office equipment

968,088

34,918

(2,764)

1,000,242

Vehicles

5,492,319

28,680

(45,062)

(1,498)

5,474,439

Equipment and computer software

974,509

30,188

(5,857)

998,840

Fixtures and fittings

7,663,899

(2,126)

7,661,773

Machinery and equipment

 

23,513,047

176,837

 

 

(91,465)

 

23,598,419

Land and buildings

 

43,111,723

 

 

(344,068)

 

42,767,655

Buildings in progress

 

11,911,194

3,678,037

 

 

(257,240)

 

15,331,991

Total

 

93,634,779

3,948,660

 

(45,062)

 

(705,018)

 

96,833,359

2.     Accumulated depreciation as of September 30, 2023 is as follows:

Depreciation

Accumulated

as of the

Foreign

Accumulated

beginning of

currency

as of the end

Class

    

the period

    

Disposals

    

Of the period

    

 translation

    

of the period

Office equipment

704,196

17,004

(1,863)

719,337

Vehicles

3,459,466

(36,049)

188,532

(52)

3,611,897

Equipment and computer software

800,110

35,963

(4,974)

831,099

Fixtures and fittings

4,800,950

184,877

(915)

4,984,912

Machinery and equipment

 

9,049,291

 

 

595,729

 

(17,194)

 

9,627,826

Land and buildings

 

6,966,931

 

 

221,298

 

(60,650)

 

7,127,579

Total

 

25,780,944

 

(36,049)

 

1,243,403

 

(85,648)

 

26,902,650

F-16

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

3.     Gross carrying amount as of September 30, 2022 is as follows:

Gross carrying amount

As of the

Additions

Foreign

As of the

beginning

from business

currency

end of the

Class

    

of the period

    

Additions

    

combination

    

Disposals

    

translation

    

period

Office equipment

908,004

(15,172)

892,832

Vehicles

5,261,979

226,051

(59,744)

(6,243)

5,422,043

Equipment and computer software

925,349

41,658

12,469

(6,667)

972,809

Fixtures and fittings

7,606,389

33,869

5,379

(5,539)

7,640,098

Machinery and equipment

 

13,017,830

107,717

 

7,047,496

 

 

(24,469)

 

20,148,574

Land and buildings

 

40,659,129

 

4,750,136

 

 

(313,148)

 

45,096,117

Buildings in progress

 

3,142,774

1,005,435

 

1,285,092

 

 

(17,941)

 

5,415,360

Total

 

71,521,454

1,414,730

 

13,100,572

 

(59,744)

 

(389,179)

 

85,587,833

4.      Accumulated depreciation as of September 30, 2022 is as follows:

Depreciation

Accumulated

as of the

Foreign

Accumulated

beginning of

Of the

currency

as of the end

Class

    

the period

    

Disposals

    

period

    

translation

    

of the period

Office equipment

638,466

17,053

(16,931)

638,588

Vehicles

2,596,905

(59,744)

226,899

(3,364)

2,760,696

Equipment and computer software

693,673

28,914

(476)

722,111

Fixtures and fittings

 

4,059,470

206,830

(23,814)

4,242,486

Machinery and equipment

 

7,205,870

 

 

679,201

 

(180,089)

 

7,704,982

Land and buildings

 

6,418,745

 

 

223,196

 

(695)

 

6,641,246

Total

 

21,613,129

 

(59,744)

 

1,382,093

 

(225,369)

 

22,710,109

The depreciation charge is included in Notes 6.3 and 6.4. The Group has no commitments to purchase property, plant and equipment items.

5.8.  Intangible assets

Intangible assets as of September 30, 2023 and June 30, 2023 included the following:

    

09/30/2023

    

06/30/2023

Gross carrying amount

 

204,300,750

 

202,306,618

Accumulated amortization

 

(31,266,214)

 

(28,522,662)

Net carrying amount

 

173,034,536

 

173,783,956

F-17

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

Net carrying amount of each class of intangible assets is as follows:

Net carrying

Net carrying

amount

amount

Class

    

09/30/2023

    

06/30/2023

Seed and integrated products

 

HB4 soy and breeding program

 

31,476,363

 

31,679,681

Integrated seed products

 

2,786,562

 

2,841,008

Crop nutrition

 

Microbiological products

 

50,506,239

 

49,508,801

Other intangible assets

 

Trademarks and patents

 

58,730,415

 

59,760,753

Software

 

1,609,367

 

1,987,690

Customer loyalty

 

22,925,590

 

23,006,023

RG/RS/OX Wheat

5,000,000

5,000,000

Total

 

173,034,536

 

173,783,956

1.      Gross carrying amount as of September 30, 2023 is as follows:

Gross carrying amount

As of the

Foreign

As of the

beginning of

currency

end of the

Class

    

the period

    

Additions

    

translation

    

period

Seed and integrated products

HB4 soy and breeding program

34,958,425

224,230

35,182,655

Integrated seed products

3,219,808

(8,178)

3,211,630

Crop nutrition

Microbiological products

 

55,645,028

 

1,723,274

(6,119)

 

57,362,183

Other intangible assets

 

Trademarks and patents

 

67,653,234

 

62,543

 

67,715,777

Software

 

5,582,411

 

1,943

(3,561)

 

5,580,793

Customer loyalty

 

30,247,712

 

 

30,247,712

RG/RS/OX Wheat

5,000,000

5,000,000

Total

 

202,306,618

 

2,011,990

(17,858)

 

204,300,750

F-18

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

2.      Accumulated amortization as of September 30, 2023 is as follows:

Amortization

Accumulated

Foreign

Accumulated as

as of beginning 

currency

of the end of the

Class

    

of the period

    

Of the period

    

translation

    

period

Seed and integrated products

  

  

  

  

HB4 soy and breeding program

3,278,744

427,548

3,706,292

Integrated seed products

378,800

47,229

(961)

425,068

Crop nutrition

Microbiological products

6,136,227

719,717

6,855,944

Other intangible assets

Trademarks and patents

7,892,481

1,092,881

8,985,362

Software

 

3,594,721

 

379,398

(2,693)

 

3,971,426

Customer loyalty

 

7,241,689

 

80,433

 

7,322,122

Total

 

28,522,662

 

2,747,206

(3,654)

 

31,266,214

3.      Gross carrying amount as of September 30, 2022 is as follows:

Gross carrying amount

As of the

Additions from

beginning 

business

Foreign currency

As of the end of

Class

    

of the period

    

Additions

    

combination

    

translation

    

the period

Seed and integrated products

 

 

  

  

 

  

HB4 soy and breeding program

 

31,371,088

361,006

31,732,094

Integrated seed products

3,181,155

3,181,155

Crop nutrition

 

 

 

Microbiological products

 

8,855,421

2,880,002

39,613,280

(3,945)

51,344,758

Other intangible assets

 

 

 

Trademarks and patents

 

12,183,045

 

3,679

55,420,441

 

67,607,165

Software

 

5,176,373

 

206,184

(1,652)

 

5,380,905

Customer loyalty

 

28,462,475

1,785,237

30,247,712

RG/RS/OX Wheat

5,000,000

5,000,000

Total

 

94,229,557

 

3,450,871

96,818,958

(5,597)

 

194,493,789

F-19

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

4.     Accumulated amortization as of September 30, 2022 is as follows:

Amortization

Accumulated as

  

Foreign

Accumulated

of beginning of

currency

as of the end

Class

    

the period

    

Of the period

    

translation

    

of the period

Seed and integrated products

HB4 soy and breeding program

 

1,568,554

 

396,701

 

1,965,255

Integrated seed products

 

43,997

13,019

57,016

Crop nutrition

 

Microbiological products

 

3,063,073

1,057,149

4,120,222

Other intangible assets

 

 

 

Trademarks and patents

 

3,916,004

 

542,868

 

4,458,872

Software

 

3,008,388

 

141,044

(1,221)

 

3,148,211

Customer loyalty

5,924,672

326,051

6,250,723

Total

17,524,688

2,476,832

(1,221)

20,000,299

The amortization charge is included in Notes 6.3 and 6.4.

5.9.  Goodwill

    

09/30/2023

    

06/30/2023

Rizobacter Argentina S.A.

 

28,080,271

 

28,080,271

Bioceres Crops S.A.

7,523,322

7,523,322

Pro farm Group, Inc.

 

76,089,749

 

76,089,749

Insumos Agroquímicos S.A.

470,090

470,090

 

112,163,432

 

112,163,432

There were no indicators of goodwill impairment.

5.10. Investment properties

    

09/30/2023

    

06/30/2023

Investment properties

 

3,675,493

 

3,589,749

 

3,675,493

 

3,589,749

5.11. Trade and other payables

    

09/30/2023

    

06/30/2023

Trade creditors

 

106,222,415

 

104,211,238

Shareholders and other related parties (Note 15)

 

27,708

 

35,292

Trade creditors - Parent company (Note 15)

 

270,645

 

644,191

Trade creditors - Joint ventures and associates (Note 15)

 

47,282,380

 

41,402,594

Taxes

 

5,138,674

 

3,561,058

Miscellaneous

 

183,536

 

953,301

 

159,125,358

 

150,807,674

F-20

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

5.12. Borrowings

    

09/30/2023

    

06/30/2023

Current

Bank borrowings

 

60,473,023

 

61,303,952

Corporate bonds

 

29,745,450

 

35,547,510

Trust debt securities

6,936,758

7,296,506

Net loans payables- Parents companies and related parties to Parent (Note 15)

 

3,565,754

 

3,491,691

 

100,720,985

 

107,639,659

Non-current

 

 

Bank borrowings

 

7,586,944

 

10,663,266

Corporate bonds

 

41,202,548

 

50,007,680

48,789,492

60,670,946

The carrying value of some borrowings as of September 30, 2023 are measured at amortized cost differ from their fair value. The following fair values measured are based on discounted cash flows (Level 3) due to the use of unobservable inputs, including own credit risk.

09/30/2023

06/30/2023

    

Amortized cost

    

Fair value

    

Amortized cost

    

Fair value

Current

Bank borrowings

 

60,473,023

 

57,553,255

 

61,303,952

 

57,209,155

Corporate Bonds

 

29,745,450

 

29,389,136

 

35,547,510

 

34,725,828

Non-current

 

 

 

 

Bank borrowings

 

7,586,944

 

5,620,759

 

10,663,266

 

10,374,646

Corporate Bonds

 

41,202,548

 

39,984,876

 

50,007,680

 

47,014,542

5.13. Secured Notes

Secured Guaranteed Notes

The carrying value of $25.9 million of the Secured Guaranteed Notes as of September 30, 2023 are measured  at amortized cost. Its fair value based on discounted cash flows, using a fair interest rate, would amount to $26.1 million.

Secured Convertible Guaranteed Notes

The carrying value of $51.0 million of the Secured Convertible Guaranteed Notes as of September 30, 2023 are measured at amortized cost. Its fair value based on discounted cash flows, using a fair interest rate, would amount to $53.3 million.

Under the terms of the Secured Convertible Guaranteed Notes, the Group is in compliance with covenants.

5.14. Employee benefits and social security

    

09/30/2023

    

06/30/2023

Salaries, accrued incentives, vacations and social security

 

9,685,549

 

9,388,639

Key management personnel (Note 15)

333,616

218,068

10,019,165

9,606,707

F-21

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

5.15. Deferred revenue and advances from customers

    

09/30/2023

    

06/30/2023

Current

 

  

 

  

Advances from customers

 

17,019,407

 

9,216,032

Deferred revenue

 

15,752,495

 

15,659,630

 

32,771,902

 

24,875,662

Non-current

 

 

Advances from customers

272,334

620,893

Deferred revenue

 

1,930,040

 

1,436,912

 

2,202,374

 

2,057,805

6.    INFORMATION ABOUT COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

6.1.  Revenue from contracts with customers

    

09/30/2023

    

09/30/2022

Sale of goods and services

 

115,628,792

 

126,113,636

Royalties

 

554,013

 

729,612

 

116,182,805

 

126,843,248

Transactions of sales of goods and services with joint ventures and with shareholders and other related parties are reported in Note 15.

6.2.  Cost of sales

Item

    

09/30/2023

    

09/30/2022

Inventories as of the beginning of the period

 

111,990,145

 

78,759,610

Business combination

 

 

11,064,908

Purchases of the period

 

71,694,655

 

79,325,509

Production costs

 

7,123,255

 

8,440,830

Foreign currency translation

 

(226,797)

 

(236,263)

Subtotal

 

190,581,258

 

177,354,594

Inventories as of the end of the period (*)

 

(118,965,477)

 

(101,678,716)

Cost of sales

71,615,781

75,675,878

(*)Net of agricultural products.

F-22

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

6.3.  R&D classified by nature

    

Research and

    

Research and

development

development

 

expenses

 

expenses

Item

 

09/30/2023

    

09/30/2022

Amortization of intangible assets

 

1,164,940

 

1,511,118

Analysis and storage

11,568

Import and export expenses

 

 

850

Depreciation of property, plant and equipment

 

157,808

 

142,373

Freight and haulage

3,917

5,300

Employee benefits and social securities

 

1,307,126

 

861,312

Maintenance

 

206,778

 

217,066

Energy and fuel

 

3,628

 

79,121

Supplies and materials

 

847,382

 

559,044

Mobility and travel

 

13,771

 

108,694

Share-based incentives

 

188,250

 

6,975

Professional fees and outsourced services

 

491,787

 

293,776

Office supplies

 

170,375

 

21,454

Information technology expenses

4,375

11,996

Insurance

 

21,049

 

10,537

Depreciation of leased assets

10,650

Miscellaneous

 

55

 

180

Total

 

4,581,241

 

3,852,014

    

09/30/2023

    

09/30/2022

R&D capitalized (Note 5.8)

 

1,947,504

 

3,241,008

R&D profit and loss

 

4,581,241

 

3,852,014

Total

 

6,528,745

 

7,093,022

F-23

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

6.4.  Expenses classified by nature and function

    

    

Selling,

    

 

general and

Production

administrative

Total

Item

costs

expenses

09/30/2023

Amortization of intangible assets

 

30,478

1,551,788

1,582,266

Analysis and storage

 

570

153,473

154,043

Commissions and royalties

 

134,592

794,058

928,650

Import and export expenses

 

67,228

120,345

187,573

Depreciation of property, plant and equipment

 

643,006

442,589

1,085,595

Depreciation of leased assets

339,378

497,821

837,199

Impairment of receivables

 

352,920

352,920

Freight and haulage

 

643,877

2,989,094

3,632,971

Employee benefits and social securities

 

2,806,939

10,238,931

13,045,870

Maintenance

 

422,757

568,155

990,912

Energy and fuel

 

163,122

16,397

179,519

Supplies and materials

 

260,043

831,454

1,091,497

Mobility and travel

 

33,407

1,348,563

1,381,970

Publicity and advertising

 

1,161,498

1,161,498

Contingencies

 

27,109

27,109

Share-based incentives

275,432

5,729,986

6,005,418

Professional fees and outsourced services

 

509,450

1,575,982

2,085,432

Office supplies and registrations fees

 

149,888

370,770

520,658

Insurance

 

27,024

473,850

500,874

Information technology expenses

 

18,361

743,163

761,524

Obsolescence

 

505,285

505,285

Taxes

 

70,819

3,766,419

3,837,238

Miscellaneous

 

21,599

178,483

200,082

Total

 

7,123,255

33,932,848

41,056,103

F-24

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

    

    

Selling,

    

 

general and

Production

administrative

Total

Item

costs

expenses

09/30/2022

Amortization of intangible assets

 

43,456

922,258

965,714

Analysis and storage

 

5,425

113,265

118,690

Commissions and royalties

 

118,960

623,459

742,419

Import and export expenses

 

98,186

256,070

354,256

Depreciation of property, plant and equipment

 

746,609

493,111

1,239,720

Depreciation of leased assets

395,972

269,805

665,777

Impairment of receivables

 

156,053

156,053

Freight and haulage

 

241,533

3,474,028

3,715,561

Employee benefits and social securities

 

3,994,761

10,041,033

14,035,794

Maintenance

 

462,743

980,742

1,443,485

Energy and fuel

 

500,359

58,400

558,759

Supplies and materials

 

339,843

491,811

831,654

Mobility and travel

 

20,940

994,919

1,015,859

Publicity and advertising

 

1,888,497

1,888,497

Contingencies

 

2,448

2,448

Share-based incentives

100,206

120,170

220,376

Professional fees and outsourced services

 

674,014

4,610,610

5,284,624

Office supplies and registrations fees

 

32,546

289,467

322,013

Insurance

 

28,430

760,276

788,706

Information technology expenses

 

13,243

993,378

1,006,621

Obsolescence

 

539,382

79,107

618,489

Taxes

 

45,049

4,130,539

4,175,588

Miscellaneous

 

39,173

155,465

194,638

Total

 

8,440,830

31,904,911

40,345,741

6.5.  Other income or expenses, net

    

09/30/2023

    

09/30/2022

Net result from commercialization of agricultural products

 

(1,316,393)

 

6,327

Expenses recovery

 

87,053

 

126,061

Other income or expenses, net

 

(2,295)

 

345,653

 

(1,231,635)

 

478,041

F-25

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

6.6.  Finance results

    

09/30/2023

    

09/30/2022

Financial costs

Interest expenses with the Parents (Note 15)

 

(97,063)

 

(149,734)

Interest expenses

 

(6,935,241)

 

(5,569,576)

Financial commissions

 

(629,553)

 

(1,060,537)

 

(7,661,857)

 

(6,779,847)

Other financial results

    

Exchange differences generated by assets

 

(9,685,066)

 

(833,428)

Exchange differences generated by liabilities

10,335,537

6,322

Changes in fair value of financial assets or liabilities and other financial results

(151,646)

(569,032)

Net gain of inflation effect on monetary items

(380,960)

107,832

117,865

(1,288,306)

7.    TAXATION

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

    

09/30/2023

    

09/30/2022

Current tax expense

 

(6,457,134)

 

(6,020,201)

Deferred tax

 

6,028,094

 

1,007,558

Total

(429,040)

(5,012,643)

    

09/30/2023

    

09/30/2022

Beginning of the period deferred tax

 

(28,472,383)

 

(24,994,569)

Additions for business combination

(16,704,770)

Charge for the period

 

6,028,094

 

1,007,558

Conversion difference

(3,718,889)

(261,014)

Total net deferred tax

 

(26,163,178)

 

(40,952,795)

The tax on the Group’s profit before tax differs from the theoretical amount that would arise using the weighted average tax rate applicable to profits of the consolidated entities as follows:

    

09/30/2023

    

09/30/2022

Earning before income tax-rate

 

(2,249,424)

 

8,924,643

Income tax expense by applying tax rate in force in the respective countries

 

(1,721,853)

 

(5,739,069)

Share of profit or loss of subsidiaries, joint ventures and associates

 

530,177

 

313,280

Stock options charge

 

(1,226,796)

 

(57,818)

Non-deductible expenses

 

(383,074)

 

(805,883)

Unrecognized deferred tax

(895,896)

Tax inflation adjustment

4,826,023

1,822,594

Result of inflation effect on monetary items and other finance results

(2,352,623)

213,857

Others

 

(100,894)

 

136,292

Income tax expenses

 

(429,040)

 

(5,012,643)

F-26

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

8.   EARNING PER SHARE

The numerators and denominators used in the calculation of basic EPS and diluted EPS are presented below:

    

09/30/2023

    

09/30/2022

Numerator

 

(Loss) profit for the period (basic EPS)

 

(4,591,634)

498,297

(Loss) profit for the period (diluted EPS)

 

(4,591,634)

498,297

Denominator

 

Weighted average number of shares (basic EPS)

 

62,846,690

60,537,110

Weighted average number of shares (diluted EPS)

 

62,846,690

61,736,679

Basic (loss) profit attributable to ordinary equity holders of the parent

(0.0731)

0.0082

Diluted (loss) profit attributable to ordinary equity holders of the parent

 

(0.0731)

0.0081

For the three-month period ended September 30, 2023 diluted EPS was equal to basic EPS as the effect of potential ordinary shares would be antidilutive.

For the three-month period ended September 30, 2022, diluted earnings per share was calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares. The Group had two categories of dilutive potential shares, share-based incentives and the convertible notes.

The stock options were included in the diluted EPS calculation for the period ended September 30, 2022 only for the tranches in which the average market price of ordinary shares during the periods was higher than the assumed proceeds per option.

Convertible notes outstanding were not included in the diluted EPS calculations for the period ended September 30, 2022 because the interest (net of tax and other changes in income or expense) per ordinary share obtainable on conversion exceeds basic earnings per share.

9.   EQUITY INFORMATION

Capital issued

As of September 30, 2023, we had (i) 100,000,000 ordinary shares ($0.0001 par value) authorized, (ii) 62,849,997 ordinary shares issued and outstanding, (iii) 1,000,000 preferred shares ($0.0001 par value) authorized, (iv) no preferred shares issued and outstanding, (v) 3,951,917 ordinary shares reserved for our equity compensation plans. Of the total issued shares, we have repurchased 2,231,761 shares of our own.

Holders of the ordinary shares are entitled to one vote for each ordinary share.

F-27

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

10.   CASH FLOW INFORMATION

Significant non-cash transactions related to investing and financing activities are as follows:

    

09/30/2023

    

09/30/2022

Investment activities

Net assets acquisition by business combination

150,510,313

Investment in-kind in other related parties (Note 15)

550,183

Capitalization of interest on buildings in progress

36,589

36,589

151,060,496

09/30/2023

    

09/30/2022

Financing activities

 

  

 

  

Capitalization of convertible notes (Note 5.13)

12,211,638

Purchase of own shares

(23,915,029)

 

 

(11,703,391)

11.   JOINT VENTURES AND ASSOCIATES

    

09/30/2023

    

06/30/2023

Assets

 

  

 

  

Synertech Industrias S.A.

 

37,550,684

 

36,026,710

Alfalfa Technologies S.R.L.

 

36,502

 

36,502

Moolec Science S.A.

 

3,233,598

 

3,233,598

 

40,820,784

 

39,296,810

    

09/30/2023

    

06/30/2023

Liabilities

 

  

 

  

Trigall Genetics S.A.

    

638,126

    

622,823

 

638,126

 

622,823

Changes in joint ventures investments and affiliates:

    

09/30/2023

    

09/30/2022

As of the beginning of the period

 

38,673,987

 

37,836,144

Foreign currency translation

 

 

100,868

Share of profit or loss

 

1,508,671

 

842,240

As of the end of the period

 

40,182,658

 

38,779,252

Share of profit or loss of joint ventures and affiliates:

    

09/30/2023

    

09/30/2022

Trigall Genetics S.A.

 

(15,303)

 

(132,117)

Synertech Industrias S.A.

1,523,974

974,357

1,508,671

842,240

F-28

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

12.   SEGMENT INFORMATION

The tables present information with respect to the Group´s reporting segments:

    

Seed and

    

    

    

 

 

integrated

 

Crop

 

Crop

Period ended September 30, 2023

 

products

protection

nutrition

Consolidated

Revenues from contracts with customers

Sale of goods and services

 

21,677,053

 

55,754,360

 

38,197,379

 

115,628,792

Royalties

 

554,013

 

 

 

554,013

Others

Initial recognition and changes in the fair value of biological assets at the point of harvest

 

87,844

 

172,118

 

150,951

 

410,913

Total

 

22,318,910

 

55,926,478

 

38,348,330

 

116,593,718

Cost of sales

 

(14,110,381)

 

(36,183,792)

 

(21,321,608)

 

(71,615,781)

Gross profit per segment

 

8,208,529

19,742,686

 

17,026,722

 

44,977,937

% Gross margin

37

%  

35

%  

44

%  

39

%

    

Seed and

    

    

    

 

 

integrated

 

Crop

 

Crop

Period ended September 30, 2022

 

products

protection

nutrition

Consolidated

Revenues from contracts with customers

Sale of goods and services

 

13,073,640

 

62,986,173

 

50,053,823

 

126,113,636

Royalties

 

729,612

 

 

 

729,612

Others

 

Initial recognition and changes in the fair value of biological assets at the point of harvest

51,451

 

89,573

 

348,982

 

490,006

Total

 

13,854,703

 

63,075,746

 

50,402,805

 

127,333,254

Cost of sales

 

(5,539,489)

 

(45,035,250)

 

(25,101,139)

 

(75,675,878)

Gross profit per segment

 

8,315,214

 

18,040,496

 

25,301,666

 

51,657,376

% Gross margin

60

%  

29

%  

50

%  

41

%

As of the current period, changes in the net realizable value of agricultural products after harvest have been excluded from segment information since those results depend on market fluctuations which are beyond the Group’s operating control. The company has recast the comparative amounts.

F-29

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

13.   FINANCIAL INSTRUMENTS – RISK MANAGEMENT

Financial instruments by category

The following tables show additional information required under IFRS 7 on the financial assets and liabilities recorded as of September 30, 2023, and June 30, 2023.

Financial assets by category

Mandatorily measured at fair

Amortized cost

value through profit or loss

Financial asset

    

09/30/2023

    

06/30/2023

    

09/30/2023

    

06/30/2023

Cash and cash equivalents

 

25,954,730

 

48,129,194

 

2,419,194

 

Other financial assets

 

502,910

 

657,612

 

14,628,202

 

11,922,317

Trade receivables

 

186,276,319

 

158,006,474

 

 

Other receivables (*)

 

11,753,573

 

12,124,724

 

 

Total

 

224,487,532

 

218,918,004

 

17,047,396

 

11,922,317

(*)

Advances expenses and tax balances are not included.

Financial liabilities by category

Mandatorily measured at fair

Amortized cost

value through profit or loss

Financial liability

    

09/30/2023

    

06/30/2023

    

09/30/2023

    

06/30/2023

Trade and other payables

 

152,753,083

 

142,582,166

 

6,372,275

 

8,225,508

Borrowings

 

149,510,477

168,310,605

 

 

Secured notes

76,911,874

75,213,146

Lease liability

13,552,751

13,889,223

Consideration for acquisition of assets

 

6,742,570

 

4,993,256

 

 

Total

 

399,470,755

 

404,988,396

 

6,372,275

 

8,225,508

F-30

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

Financial instruments measured at fair value

Measurement at fair value at 09/30/2023

    

Level 1

    

Level 2

    

Level 3

Financial assets at fair value

US Treasury bills

9,719,486

Mutual funds

3,236,702

Other investments

 

1,672,014

 

 

Financial liability at fair value

    

    

    

Trade and other payables

6,372,275

Measurement at fair value at 06/30/2023

    

Level 1

    

Level 2

    

Level 3

Financial assets at fair value

US Treasury bills

9,163,298

Mutual funds

1,596,539

Other investments

1,162,480

Financial liability at fair value

Trade and other payables

8,225,508

Estimation of fair value

The fair value of marketable securities, mutual funds and US Treasury Bills is calculated using the market approach using quoted prices in active markets for identical assets. The quoted marked price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

The Group’s financial liabilities, which were not traded in an active market, were determined using valuation techniques that maximize the use of available market information, and thus rely as little as possible on specific estimates of the entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instruments are included in level 2.

If one or more of the significant inputs is not based on observable market data, the instruments are included in level 3.

The Group’s policy is to recognize transfers between different categories of the fair value hierarchy at the time they occur or when there are changes in the circumstances that cause the transfer. There were no transfers between levels of the fair value hierarchy. There were no changes in economic or business circumstances affecting fair value.

Financial instruments not measured at fair value

The financial instruments not measured at fair value include cash and cash equivalents, trade accounts receivable, other accounts receivable, trade payables and other debts, borrowings, financed payments and convertible notes.

The carrying value of financial instruments not measured at fair value does not differ significantly from their fair value, except for borrowings (Note 5.12).

Management estimates that the carrying value of the financial instruments measured at amortized cost approximates their fair value.

F-31

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

Currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rate. Currency on foreign exchange risk arises when the Group enters into transactions denominated in a currency other than its functional currency.

The table below sets forth our net exposure to currency risk as of September 30, 2023:

Net foreign currency position

    

09/30/2023

Amount expressed in US$

 

(5,353,860)

Considering only this net currency exposure as of September 30, 2023 if an US Dollar revaluation or depreciation in relation to other foreign currencies with the remaining variables remaining constant, would have a positive or a negative impact on comprehensive income as a result of foreign exchange gains or losses. We estimate that a devaluation or an appreciation of the US Dollar other currencies of 10% during the period ended September 30, 2023 would have resulted in a net pre-tax loss or gain of approximately $0.5 million.

14. LEASES

Right-of-use leased asset

    

09/30/2023

    

06/30/2023

Book value at the beginning of the period/year

 

21,163,192

 

15,828,032

Additions of the period/year

 

1,072,418

 

3,154,950

Additions from business combination

3,005,000

Disposals

(461,631)

(1,839,921)

Exchange differences

(513,269)

1,015,131

Book value at the end of the period/year

 

21,260,710

 

21,163,192

Depreciation

 

09/30/2023

    

06/30/2023

Book value at the beginning of the period/year

7,226,617

3,684,006

Depreciation of the period/year

837,199

3,565,894

Disposals

 

(274,431)

 

(171,870)

Exchange differences

 

(47,874)

 

148,587

Accumulated depreciation at the end of the period/year

 

7,741,511

 

7,226,617

Total

 

13,519,199

 

13,936,575

Lease liability

    

09/30/2023

    

06/30/2023

Book value at the beginning of the period/year

 

13,889,223

 

11,751,284

Additions of the period/year

 

1,072,418

 

3,154,950

Additions from business combination

3,245,000

Interest expenses, exchange differences and inflation effects

 

(238,851)

 

(406,494)

Payments of the period/year

 

(1,170,039)

 

(3,855,517)

Total

 

13,552,751

 

13,889,223

F-32

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

Lease Liabilities

    

09/30/2023

    

06/30/2023

Non-current

 

9,225,862

 

10,030,524

Current

 

4,326,889

 

3,858,699

Total

 

13,552,751

 

13,889,223

The recognized right-of-use assets relate to the following types of assets:

    

09/30/2023

    

06/30/2023

Machinery and equipment

 

3,655,741

 

3,655,741

Vehicles

 

1,433,616

 

1,475,581

Equipment and computer software

 

1,011,490

 

903,306

Land and buildings

 

15,159,863

 

15,128,564

 

21,260,710

 

21,163,192

The incremental borrowing rate used was 2.13 %.

15.   SHAREHOLDERS AND OTHER RELAED PARTIES BALANCES AND TRANSACTIONS

During the period ended September 30, 2023, and 2022, the transactions between the Group and related parties, and the related balances owed by and to them, are as follows:

Value of transactions for the period ended

Party

    

Transaction type

    

09/30/2023

    

09/30/2022

Joint ventures and associates

 

Sales and services

 

6,801,117

 

17,083,027

Joint ventures and associates

 

Purchases of goods and services

 

(20,691,171)

 

(25,314,814)

Key management personnel

 

Salaries, social security benefits and other benefits

 

(6,702,803)

 

(648,494)

Shareholders and other related parties

 

Sales of goods and services

 

1,590,568

 

261,418

Shareholders and other related parties

Purchases of goods and services

(196,051)

(239,772)

Shareholders and other related parties

In-kind contributions

550,183

Shareholders and other related parties

Net loans granted/(cancelled)

(1,609)

Shareholders and other related parties

Interest expenses

(23,000)

Parent company and related parties to Parent (Note 6.6)

 

Interest expenses

 

(97,063)

 

(149,734)

Total

 

 

(19,318,403)

 

(8,459,795)

Amounts receivable from related parties

Party

    

Transaction type

    

09/30/2023

    

06/30/2023

Shareholders and other related parties

 

Other receivables

 

1,368,373

 

Shareholders and other related parties

 

Other receivables

 

2,919,431

 

3,792,429

Joint ventures and associates

 

Trade debtors

 

781,451

 

865,627

Joint ventures and associates

 

Other receivables

 

6,699,863

 

6,334,219

Total

 

11,769,118

 

10,992,275

F-33

Table of Contents

Graphic

NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in US$, except otherwise indicated)

Amounts payable to related parties

Party

    

Transaction type

    

09/30/2023

    

06/30/2022

Parent company and related parties to Parent

Trade creditors

(270,645)

(644,191)

Parent company and related parties to Parent

Net loans payables

(3,565,754)

(3,491,691)

Key management personnel

 

Salaries, social security benefits and other benefits

 

(333,616)

 

(218,068)

Shareholders and other related parties

 

Trade and other payables

 

(27,708)

 

(35,292)

Joint ventures and associates

 

Trade creditors

 

(47,282,380)

 

(41,402,594)

Total

 

(51,480,103)

 

(45,791,836)

16.   KEY MANAGEMENT PERSONNEL COMPENSATION

The compensation of directors and other members of key management personnel, including social contributions and other benefits, were as follows for the period ended September 30, 2023, and 2022.

    

09/30/2023

    

09/30/2022

Salaries, social security and other benefits

 

509,135

 

421,143

Share-based incentives

6,193,668

227,351

Total

 

6,702,803

 

648,494

17.   SHARE-BASED PAYMENT

Pursuant to the 2023 Omnibus Equity Incentive Plan approved on May 12, 2023, in August 2023 the Board has granted the following stock options plan to certain directors, executives and management of the Group.

-

Past Share Option plan: immediately vested options with a strike price between $11.93 and $13.24.

-

Base Share Option plan: to vest and become exercisable in equal installments on June 30, 2023, June 30, 2024, and June 30, 2025, with a strike price of $10.47.

-

Performance Share Option plan: to vest and become exercisable if the Company’s fiscal year 2025 EBITDA reaches at least US$120 million, at 0% of the award, and linearly thereafter up to 100% of the awarded options when reaching at least US$150 million. This option has also a strike price of $10.47.

The fair value of the stock options at the grant date was estimated using the “Black-Scholes” model considering the terms and conditions under which the stock options were granted and adjusted to consider the possible dilutive effect of the future exercise of options. As of September 30, 2023, the expenses associated with share-based incentive plans are included in results within “Share-based incentives” along with the associated increase in net worth.

18.   CONTINGENCIES, COMMITMENTS AND RESTRICTIONS ON THE DISTRIBUTION OF PROFITS

There were no other significant changes to the contingencies, commitments and restrictions on the distribution of profits from the disclosure made in the Consolidated financial statement as of June 30, 2023.

19.   EVENTS OCCURRING AFTER THE REPORTING PERIOD

Subsequent to September 30, 2023, there have been no other situations or circumstances that may require significant adjustments or further disclosure in these consolidated financial statements that were not mentioned above.

F-34